Cargando…
A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
BACKGROUND: Ixabepilone (BMS-247550), an epothilone B analog, is a microtubule stabilizing agent which has shown activity in several different tumor types and preclinical models in melanoma. In an open label, one-arm, multi-center phase II trial the efficacy and toxicity of this epothilone was inves...
Autores principales: | Ott, Patrick A., Hamilton, Anne, Jones, Amanda, Haas, Naomi, Shore, Tsiporah, Liddell, Sandra, Christos, Paul J., Doyle, L. Austin, Millward, Michael, Muggia, Franco M., Pavlick, Anna C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808339/ https://www.ncbi.nlm.nih.gov/pubmed/20098694 http://dx.doi.org/10.1371/journal.pone.0008714 |
Ejemplares similares
-
Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009) -
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
por: DeConti, R C, et al.
Publicado: (2010) -
Synthesis, Microtubule-Binding Affinity, and Antiproliferative Activity of New Epothilone Analogs and of an EGFR-Targeted Epothilone-Peptide Conjugate
por: Gaugaz, Fabienne Zdenka, et al.
Publicado: (2019) -
Profile and potential of ixabepilone in the treatment of pancreatic cancer
por: Smaglo, Brandon G, et al.
Publicado: (2014) -
Tissue distribution and tumor uptake of folate receptor–targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration
por: Shen, Hong, et al.
Publicado: (2016)